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Cell lines producing biopharmaceuticals with high yield
and high quality in a regulatory compliant environment
are a prerequisite for cost effective bioproductions. The
development of these production cell lines often
includes screening strategies combined with gene ampli-
fication and limited dilution experiments, a time con-
suming process. Especially gene amplification tends to
interfere with clonal stability. Limited dilution, especially
using a serum-free culture environment is prone to fail-
ure and low clone yields.
We present here the SEFEX platform technology for
the development of non-amplified high yield production
cell lines. The strategy is based on a regulatory compli-
ant method for transfection and single cell cloning using
a proprietary, fully tested, CHO-K1 host cell line
adapted to chemically defined medium. Fast track cell
lines were generated by selection of single cell derived
clones within 2.5 months after transfection. 1.0 g/L pro-
duct concentration were achieved after two rounds of
process development using these cell lines. Optimized
cell lines were developed based on fast track cell lines
employing a second transfection. These cell lines were
capable for production of 2.6 g/L during an early phase
of process development.
Cell line development with the SEFEX technology
comprises steps carried out entirely under serum-free
conditions including transfection, selection, and single
cell cloning. Fast track cell lines were developed within
2.5 months by transfection and selection of stably trans-
fected cells followed by single cell cloning. During single
cell cloning, semi-automated photo documentation at
the single cell level is used to assure and document
clonality in a regulatory compliant manner. Table 1
summarizes cell specific productivity and product con-
centration in fed-batch processes. More than 1.0 g/L
were achieved in a GMP process at 300 L scale after
two steps of process development followed by scale-up
development. A similar scale-up strategy including GMP
production was summarized by Landauer et al. in this
issue [1]. Nevertheless, production of proteins that are
difficult to express like, IgG C in Table 1, suffered from
low productivity and low yield. Optimized cell lines,
which were obtained by a second serial transfection of
the antibody expression vector including regulatory
sequences, were suitable to deliver high rates of anti-
body production. The productivity of IgG C was
improved 6-fold to18 pg/c/d. This allowed production
of the difficult to express protein at a product concen-
tration of 1.1 g/L in fed-batch mode (Table 1). Other
examples of optimized cell lines provided product con-
centrations of 1.7 g/L without any optimization during
cell line development (IgG A, Table 1), or 2.6 g/L after
two steps of upstream process development at 1 L bior-
eactor scale (IgG B, Table 1, Figure 1).
Figure 1 shows growth curves of the fast-track and
optimized cell line producing IgG B. Optimization of
maximum viable cell density was not addressed during
upstream process development so far. This optimization
is currently ongoing and leaves room for further
improvements. Specific productivity of the optimized
cell lines varied between 18 and 36 pg/c/d, which was
equivalent to a two- to six-fold improvement compared
to the fast track cell lines. Productivity was suitable for
production of high volume products. Scale-up to 300 L
stirred tank and 1000 L wave bioreactor for production
of clinical phase II drug product was shown for produc-
tion cell lines generated with the SEFEX platform
technology.
The SEFEX platform technology for the development
of non-amplified high yield production cell lines is
based on a regulatory compliant, proprietary CHO-K1
host cell line adapted to chemically defined medium.
Fast track cell lines, which were available within 2.5
months produced 1.0 g/L product. Optimized cell lines,
which were developed based on fast track cell lines,
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any medium, provided the original work is properly cited.were capable for production of 2.6 g/L in early phase of
process development. Using the SEFEX platform tech-
nology, all development steps were carried out under
entirely serum-free or chemically defined media condi-
tions including transfection, selection, and single cell
cloning. Clonality was assured and documented in a reg-
ulatory compliant manner using photo documentation
of single cells in cell cloning experiments. The serial
transfection cell line development strategy described
here provides the possibility to develop production cell
lines meeting industrial demands employing simplest
process development procedures within minimized time
frames.
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Table 1 Cell specific productivity and product concentration obtained with fast track cell lines and optimized cell
lines.
specific productivity [pg/cell/day] product concentration fed-batch [g/L]
Project fast track cell line optimised cell line fast track cell line optimised cell line
1 (IgG A) 11 36 0.6
a 1.7
a
2 (IgG B) 12 25 1.0
b 2.6
c
3 (IgG C) 3 18 no fed-batch 1.1
d
a Fed-batch experiment during cell line development without any optimization using chemically defined basal medium and proprietary CeloFeed.
b Fed-batch
experiment after two steps of process development and scale-up to 10 L using chemically defined basal and feed medium.
c Fed-batch experiment at 1 L
bioreactor scale after two steps of optimization using chemically defined basal medium and proprietary CeloFeed.
d Fed-batch experiment at shake flask scale
using chemically defined basal medium and proprietary CeloFeed.
Figure 1 Fed-batch experiments for production of IgG B. The fast-track cell line (left hand graph) was cultivated at 10 L scale after two steps of
process development and scale up using chemically defined basal and feed medium. The optimized cell line (right hand graph) was cultivated
at 1 L scale after basal media and feed media screening. A chemically defined medium was used in combination with the proprietary feed
solution CeloFeed.
Greulich et al. BMC Proceedings 2011, 5(Suppl 8):P43
http://www.biomedcentral.com/1753-6561/5/S8/P43
Page 2 of 2